Biomarker-based prediction of fatal and non-fatal cardiovascular outcomes in individuals with diabetes mellitus
Authors' conclusion
Biomarkers improve cardiovascular risk prediction in individuals with and without diabetes and facilitate the identification of individuals with diabetes at highest risk for cardiovascular events.
Study context
- Population
- Individuals of the European population, Biomarker for Cardiovascular Risk Assessment across Europe consortium6,090 (6.4%) with diabetes
- Participants
- 95,292 individuals
- Comparison
- Diabetes vs no diabetes; biomarkers added to classical risk factors
- Diabetesn = 6,090
- Outcome
- Fatal and non-fatal CV events
- Follow-up
- Median 9.9 years
Methodological detailspooled individual-level data, multicohort consortium (BiomarCaRE)
- Pooled individual-level data
- Multicohort consortium (BiomarCaRE)
Performance
As reported in the abstract
Estimate (95% CI)
Diabetesvs No diabetesadjusted for classical risk factors and biomarkers
HR 2.11(1.92–2.32)
hs-cTnI
HR per IQR 1.08(1.04–1.12)
NT-proBNP
HR per IQR 1.44(1.37–1.53)
hs-CRP
HR per IQR 1.27(1.21–1.33)
- Adding biomarkers improved prediction (likelihood ratio test for nested models)
- P < 0.001
- C-index increased
- 0.81
Further findings
Life lost, diabetes with elevated biomarkers vs diabetes without (specific cut-offs)
- Median years of life lost by high-risk group
- 15.5
Original publication
Biomarker-based prediction of fatal and non-fatal cardiovascular outcomes in individuals with diabetes mellitus. Eur J Prev Cardiol. Published 20 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →